START FREE TRIAL
Home Healthcare Illumina, Inc.

Illumina, Inc.

$19.00

SKU: ILMN Category:

Description

Illumina’s $30 Million Guidance Raise — Is Wall Street Missing Its Clinical Recovery?

 

Illumina, Inc. reported third-quarter 2026 financial results marked by revenue and earnings surpassing prior guidance, driven largely by strong clinical sequencing demand and elevated placements of its NovaSeq X platform. Revenue reached $1.17 billion, reflecting a 4.7% year-over-year increase on a rest-of-world organic basis, supported by a 6% year-over-year rise in sequencing consumables revenue. The company highlighted continued adoption in clinical markets, which grew 14%, contrasted with a 6% decline in research and applied markets, a trend the company expects to persist through 2026. Sequencing instrument revenue declined modestly by 2% year-over-year, impacted by geographic softness despite increased NovaSeq X placements. Operational margins expanded to 25% in Q3, surpassing guidance by 100 basis points, aided by tariff refunds excluded from non-GAAP results. Earnings per share rose 7% to $1.44, with free cash flow of $378 million bolstering the balance sheet, which ended the quarter with $1.